

# Thrombus Imaging Characteristics and Outcomes in Acute Ischemic Stroke Patients Undergoing Endovascular Treatment

Citation for published version (APA):

Dutra, B. G., Tolhuisen, M. L., Alves, H. C. B. R., Treurniet, K. M., Kappelhof, M., Yoo, A. J., Jansen, I. G. H., Dippel, D. W. J., van Zwam, W. H., van Oostenbrugge, R. J., da Rocha, A. J., Lingsma, H. F., van der Lugt, A., Roos, Y. B. W. E. M., Marquering, H. A., Majoie, C. B. L. M., & MR CLEAN Registry Investigators (2019). Thrombus Imaging Characteristics and Outcomes in Acute Ischemic Stroke Patients Undergoing Endovascular Treatment. *Stroke*, *50*(8), 2057-2064. <https://doi.org/10.1161/STROKEAHA.118.024247>

**Document status and date:**

Published: 01/08/2019

**DOI:**

[10.1161/STROKEAHA.118.024247](https://doi.org/10.1161/STROKEAHA.118.024247)

**Document Version:**

Publisher's PDF, also known as Version of record

**Document license:**

Taverne

**Please check the document version of this publication:**

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

**Take down policy**

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

# Thrombus Imaging Characteristics and Outcomes in Acute Ischemic Stroke Patients Undergoing Endovascular Treatment

Bruna G. Dutra, MD\*; Manon L. Tolhuisen, MSc\*; Heitor C.B.R. Alves, MD; Kilian M. Treurniet, MD, MSc; Manon Kappelhof, MD; Albert J. Yoo, MD, PhD; Ivo G.H. Jansen, MD, PhD; Diederik W.J. Dippel, MD, PhD; Wim H. van Zwam, MD, PhD; Robert J. van Oostenbrugge, MD, PhD; Antônio J. da Rocha, MD, PhD; Hester F. Lingsma, PhD; Aad van der Lugt, MD, PhD; Yvo B.W.E.M. Roos, MD, PhD; Henk A. Marquering, PhD; Charles B.L.M. Majoie, MD, PhD; the MR CLEAN Registry Investigators†

**Background and Purpose**—Thrombus imaging characteristics have been reported to be useful to predict functional outcome and reperfusion in acute ischemic stroke. However, conflicting data about this subject exist in patients undergoing endovascular treatment. Therefore, we aimed to evaluate whether thrombus imaging characteristics assessed on computed tomography are associated with outcomes in patients with acute ischemic stroke treated by endovascular treatment.

**Methods**—The MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) Registry is an ongoing, prospective, and observational study in all centers performing endovascular treatment in the Netherlands. We evaluated associations of thrombus imaging characteristics with the functional outcome (modified Rankin Scale at 90 days), mortality, reperfusion, duration of endovascular treatment, and symptomatic intracranial hemorrhage using univariable and multivariable regression models. Thrombus characteristics included location, clot burden score (CBS), length, relative and absolute attenuation, perviousness, and distance from the internal carotid artery terminus to the thrombus. All characteristics were assessed on thin-slice ( $\leq 2.5$  mm) noncontrast computed tomography and computed tomography angiography, acquired within 30 minutes from each other.

**Results**—In total, 408 patients were analyzed. Thrombus with distal location, higher CBS, and shorter length were associated with better functional outcome (adjusted common odds ratio, 3.3; 95% CI, 2.0–5.3 for distal M1 occlusion compared with internal carotid artery occlusion; adjusted common odds ratio, 1.15; 95% CI, 1.07–1.24 per CBS point; and adjusted common odds ratio, 0.96; 95% CI, 0.94–0.99 per mm, respectively) and reduced duration of endovascular procedure (adjusted coefficient B,  $-14.7$ ; 95% CI,  $-24.2$  to  $-5.1$  for distal M1 occlusion compared with internal carotid artery occlusion; adjusted coefficient B,  $-8.5$ ; 95% CI,  $-14.5$  to  $-2.4$  per CBS point; and adjusted coefficient B,  $7.3$ ; 95% CI,  $2.9$ – $11.8$  per mm, respectively). Thrombus perviousness was associated with better functional outcome (adjusted common odds ratio, 1.01; 95% CI, 1.00–1.02 per Hounsfield units increase). Distal thrombi were associated with successful reperfusion (adjusted odds ratio, 2.6; 95% CI, 1.4–4.9 for proximal M1 occlusion compared with internal carotid artery occlusion).

**Conclusions**—Distal location, higher CBS, and shorter length are associated with better functional outcome and faster endovascular procedure. Distal thrombus is strongly associated with successful reperfusion, and a pervious thrombus is associated with better functional outcome. (*Stroke*. 2019;50:2057-2064. DOI: 10.1161/STROKEAHA.118.024247.)

**Key Words:** computed tomography angiography ■ endovascular procedure ■ reperfusion ■ stroke ■ thrombectomy ■ thrombus

Received November 14, 2018; final revision received March 6, 2019; accepted April 1, 2019.

From the Departments of Radiology and Nuclear Medicine (B.G.D., H.C.B.R.A., K.M.T., M.K., I.G.H.J., C.B.L.M.M.), Biomedical Engineering and Physics (B.G.D., M.L.T., H.C.B.R.A., H.A.M.), and Neurology (Y.B.W.E.M.R.), Academic Medical Center, Amsterdam, the Netherlands; Departments of Radiology (A.v.d.L.), Neurology (D.W.J.D.), and Public Health (H.F.L.), Erasmus MC University Medical Center, Rotterdam, the Netherlands; Division of Interventional Neuroradiology, Department of Radiology, Texas Stroke Institute, Plano (A.J.Y.); Departments of Radiology (W.H.v.Z) and Neurology (R.J.v.O.), and Cardiovascular Research Institute Maastricht (W.H.v.Z., R.J.v.O.), Maastricht University Medical Center, the Netherlands; and Department of Radiology, Irmandade Santa Casa de Misericórdia de São Paulo, Brazil (B.G.D., H.C.B.R.A., A.J.d.R.).

\*Dr Dutra and M.L. Tolhuisen contributed equally.

†A list of all MR CLEAN Registry Investigators is given in the [online-only Data Supplement](#).

Guest Editor for this article was Sean I. Savitz, MD.

The online-only Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.118.024247>.

Correspondence to Bruna G. Dutra, MD, Department of Radiology and Nuclear Medicine and Department of Biomedical Engineering and Physics, Academic Medical Center, P.O. Box 22660, Amsterdam 1100DD, the Netherlands. Email [bruna.gdutra@gmail.com](mailto:bruna.gdutra@gmail.com)

© 2019 American Heart Association, Inc.

*Stroke* is available at <https://www.ahajournals.org/journal/str>

DOI: 10.1161/STROKEAHA.118.024247

**See related article, p 1948**

**T**hrombus location is the only thrombus imaging characteristic currently evaluated in the assessment of patients with acute ischemic stroke (AIS) in daily practice.<sup>1,2</sup> However, recent studies have reported other thrombus imaging characteristics that may be useful for predicting functional outcome and reperfusion in AIS.<sup>3-6</sup> Associations between thrombus imaging characteristics and these outcomes have been evaluated primarily in patients undergoing intravenous thrombolysis (IVT).<sup>3,6-9</sup> Conflicting data exist about the associations between thrombus characteristics and outcomes after endovascular treatment (EVT) of AIS.

Because EVT has emerged as the mainstay of treatment for AIS because of proximal intracranial occlusions, identification of imaging biomarkers that predict EVT outcomes would be highly relevant to acute stroke management. The aim of the present study is to evaluate the associations between thrombus imaging characteristics and outcomes in patients undergoing EVT in the MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) Registry.

## Methods

### Patient Selection

The MR CLEAN Registry is an ongoing, prospective, observational, multicenter study at 16 intervention hospitals in the Netherlands. It includes all patients with AIS who underwent EVT since the completion of the MR CLEAN trial in March 2014. Patients were treated with IVT before EVT if eligible. The central medical ethics committee of the Erasmus Medical Centre Rotterdam, the Netherlands, evaluated the study protocol and granted permission (MEC-2014-235) to perform the study as a registry.<sup>10</sup> For the purpose of this analysis, we used the following inclusion criteria: intracranial proximal occlusion in the anterior arterial circulation; age  $\geq 18$  years; groin puncture within 6.5 hours after stroke onset; and treatment in an MR CLEAN trial center. The current study reports on patients registered in the MR CLEAN Registry between March 2014 and June 2016. Source data of this study are available from the corresponding author on reasonable request.

### Imaging Analyses

Patients underwent the MR CLEAN Registry imaging protocol (Methods I in the [online-only Data Supplement](#)). We included patients with available thin-slice ( $\leq 2.5$  mm) baseline noncontrast computed tomography (NCCT) and computed tomography angiography (CTA), acquired within 30 minutes from each other. All baseline NCCT and CTA scans were automatically aligned using rigid registration with Elastix software.<sup>11</sup> In case of suboptimal alignment, adjustments were performed by manual rigid registration, with Mevislab (by Dr Dutra). Scans with uncorrectable registration errors, artifacts, excessive noise, or poor contrast opacification on CTA were excluded. To prevent bone artifacts that might interfere with the thrombus attenuation measurements, we excluded patients with an intracranial arterial occlusion restricted to the petrous, cavernous, and clinoid segments of the internal carotid artery (ICA). Calcified thrombi were also excluded because of their higher attenuation values (related to calcium composition) compared with the attenuation values of noncalcified thrombi, and because calcification produces streak and partial volume artifacts, which can cause overestimation of the thrombus size.

We evaluated the following thrombus imaging characteristics: location, clot burden score (CBS), absolute and relative attenuation, perviousness, length, and distance from the ICA terminus to the thrombus (DT). The observers were blinded for all clinical

data except for symptom side. The assessments of thrombus imaging characteristics are detailed in the [online-only Data Supplement](#) (Methods II and Figures I and II in the [online-only Data Supplement](#)).

### Outcome Measures

The primary outcome was defined as the modified Rankin Scale (mRS) score at 90 days. The mRS is a 7-point scale ranging from 0 (no symptoms) to 6 (death). Secondary outcomes were good functional outcome (score of 0–2 on the mRS), mortality at 90 days, reperfusion status assessed on digital subtraction angiography according to the extended Thrombolysis in Cerebral Infarction (eTICI) score,<sup>12</sup> duration of EVT, and symptomatic intracranial hemorrhage (sICH). The eTICI score was assessed by the MR CLEAN Registry imaging core lab, based on the degree of reperfusion in the downstream territory of the original occlusion on digital subtraction angiography. The eTICI score ranges from 0 (no reperfusion or antegrade flow beyond occlusion site) to 3 (complete reperfusion), including a 2C category (90%–99% reperfusion).<sup>12,13</sup> Successful reperfusion status was defined as eTICI scores of 2b, 2c, or 3.

Duration of EVT was determined in patients who underwent an actual thrombectomy, and this outcome was measured from artery puncture (time zero) to the time that successful reperfusion was achieved or to the end of procedure if no successful reperfusion was achieved. The following patients were not considered in the assessments of duration of EVT: no target occlusion depicted on digital subtraction angiography (recanalization of primary occlusion on the first run), or unreachable target occlusion (ie, due to vascular tortuosity, stenosis, or occlusion of the carotid artery).


### Statistical Analysis

#### Subject Characteristics

We present the baseline clinical and imaging characteristics of our study population and of the full published MR CLEAN Registry data set<sup>10</sup> using median and interquartile range (IQR) for continuous variables and frequencies and percentages for categorical variables. Correlation chart was performed to summarize the data about the distribution of each thrombus imaging characteristics, and to investigate whether thrombus imaging characteristics are correlated to each other, using the Spearman correlation coefficient for non-normally distributed data and the Pearson correlation coefficient for normally distributed data.

#### Associations Between Thrombus Imaging Characteristics and Outcomes

Univariable and multivariable regression models were used to evaluate the association between thrombus imaging characteristics and outcomes. Ordinal logistic regression was used to assess the associations between thrombus characteristics and mRS as primary outcome measurement, resulting in an unadjusted and adjusted common odds ratio (common OR and adjusted common OR, respectively) for a 1-step shift towards better functional outcome. Unadjusted and adjusted binary logistic regression models were used to assess the associations with good functional outcome, successful reperfusion, mortality, and sICH as secondary outcomes. Unadjusted and adjusted linear regressions were performed to evaluate the associations with a duration of EVT as a secondary outcome measurement. We adjusted for age, prestroke mRS, time from stroke onset to artery puncture, IVT, diabetes mellitus, previous myocardial infarction, previous stroke, hypertension, and atrial fibrillation. Use of anticoagulants and antiplatelet agents was added to the adjustments for the analyses with reperfusion status, duration of EVT, and sICH as outcome measurements. In developing the multivariable model, we did not consider Alberta Stroke Program Early CT Score, baseline National Institutes of Health Stroke Scale score, and collaterals as potential confounders because we assumed they were in the causal pathway between thrombus and outcomes, as the following: proximal arterial thrombi (low CBS, short DT, and longer thrombus length) are hypothesized to



**Figure.** Flow chart of the patient selection process. CTA indicates computed angiography tomography; EVT, endovascular treatment; ICA, internal carotid artery; MR CLEAN, Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; and NCCT, noncontrast computed tomography.

cause impaired collateral filling<sup>14,15</sup> and greater areas of hypodensity on NCCT, consequently leading to a lower Alberta Stroke Program Early CT Score, higher severity stroke scale (National Institutes of Health Stroke Scale score),<sup>16</sup> poorer functional outcome and higher chances of sICH. Interaction terms between primary treatment modalities and thrombus burden (CBS and length) were performed for the achieved outcomes.

All statistical analyses were performed using R (R Foundation for Statistical Computing, version 3.5.1). For the regression analyses, missing data were imputed using multiple imputation.<sup>17</sup> Missing mRS scores at 90 days or mRS scores of 0–5 assessed at <30 days from stroke were imputed. We performed multiple imputation using the variables listed in the [online-only Data Supplement](#) (Table I in the [online-only Data Supplement](#)).

## Results

### Subject Characteristics

Overall, 408 patients were included in our analysis (Figure). The median age was 70 years (IQR, 59–80), 54% (n=222) were male, and the median National Institutes of Health Stroke Scale score was 16 (IQR, 11–20). Of all patients eligible for EVT, 87% (n=356/408) underwent EVT with thrombus retrieval, and the most used primary treatment modality was the stent retriever (75%). The median duration of EVT was 62 minutes (IQR, 44–90 minutes). Thrombus location was the

most commonly distal M1 (36%) followed by ICA (25%), and proximal M1 (24%). CBS of 8 to 10 was observed in 29% of patients (n=102/353). Median values of thrombus length, DT, absolute attenuation, relative attenuation, and perviousness were 12.7 mm (IQR, 8.7–17.9 mm), 8.3 mm (IQR, 0–14.4 mm), 51.8 Hounsfield units (HU; IQR 45–58 HU), 1.33 (IQR, 1.19–1.52), and 5 HU (–0.2 to 12.3 HU). IVT was administered in 77% of patients (n=314). Baseline characteristics in our cohort were similar to the full MR CLEAN Registry data set<sup>10</sup> (Table 1).

Results of data distribution and correlation analyses among thrombus characteristics are detailed in the [online-only Data Supplement](#) (Figure III in the [online-only Data Supplement](#)). Longer thrombi were statistically correlated with shorter DT, more proximal location, lower CBS, lower perviousness, and higher absolute attenuation (correlation coefficients of –0.44, –0.45, –0.53, –0.23, and +0.35, respectively).

### Associations Between Thrombus Imaging Characteristics and Outcomes

#### Primary Outcome

More distal thrombus location and higher CBS values were significantly associated with improved functional outcome in the unadjusted and adjusted models. Thrombus located in the distal M1 segment had an increased odds of having improved functional outcome compare to ICA thrombus (adjusted common OR, 3.27; 95% CI, 2.03–5.29). Unadjusted and adjusted common ORs per point CBS were 1.12 (95% CI, 1.04–1.20) and 1.15 (95% CI, 1.07–1.24). A longer thrombus was associated with reduced likelihood of improved functional outcome (adjusted common OR, 0.96; 95% CI, 0.94–0.99 per mm). An increased chance of improved functional outcome was observed in a more pervious thrombus (adjusted common OR, 1.01; 95% CI, 1.00–1.02 per HU increase) in the adjusted analyses (Table 2).

#### Secondary Outcomes

##### Favorable Functional Outcome (mRS Score of 0–2)

Favorable functional outcome was observed in 38% of patients (n=155). Associations between thrombus imaging characteristics and dichotomized functional outcome (mRS score of 0–2) were similar to the primary functional outcome analyses, as listed in Table 2. A statistically significant interaction was observed between CBS and primary EVT modality. For higher CBS, patients treated with stent-retriever had increased chances of having favorable functional outcome compared with others EVT modalities (Figure IV in the [online-only Data Supplement](#)). No statistically significant interaction was observed between thrombus length and primary treatment modality.

##### Mortality at 90 Days

Death at 90 days was observed in 26.2% of patients (n=107). This outcome was significantly associated with more proximally located thrombi (adjusted OR [aOR], 0.29; 95% CI, 0.14–0.61 for proximal M1 thrombi compared with ICA occlusions), lower CBS (aOR, 0.85; 95% CI, 0.77–0.95), and longer thrombus length (aOR, 1.04; 95% CI, 1.01–1.07), as detailed in Table 2.

**Table 1. Baseline Characteristics of the Registry Subgroup Included in Our Study and of the MR CLEAN Registry Database**

	MR CLEAN Registry Subgroup Included (n=408)	Full MR CLEAN Registry Database (n=1488)
<b>Baseline clinical variables</b>		
Age, median (IQR)	70 (59 to 80); n=408	71 (60 to 80); n=1488
Sex (men), n (%)	222 (54.4); n=408	794 (53.3); n=1488
NIHSS baseline, median (IQR)	16 (11 to 20); n=398	16 (11 to 20); n=1458
SBP, mm Hg, median (IQR)	149 (131 to 163); n=397	150 (125 to 175); n=1446
DBP, mm Hg, median (IQR)	80 (70 to 90); n=396	80 (70 to 91); n=1439
<b>Medical history, n (%)</b>		
Diabetes mellitus	75 (18.6); n=404	255 (17.2); n=1479
Hypertension	202 (50.4); n=401	745 (50.7); n=1469
Dyslipidemia	116 (29.1); n=398	431 (29.9); n=1441
Current smoking	97 (24); n=404	338 (22.9); n=1474
Previous stroke	63 (15.6); n=404	249 (16.8); n=1479
Previous myocardial infarction	73 (18.4); n=397	228 (15.6); n=1459
Previous atrial fibrillation	84 (20.9); n=401	327 (22.3); n=1466
Anticoagulation	131 (33.2); n=395	493 (33.6); n=1469
<b>Prestroke modified Rankin Scale score, n (%)</b>		
0	253/397 (63.7)	991/1461 (67.8)
1	52/397 (13.1)	189/1461 (12.9)
2	36/397 (9.1)	110/1461 (7.5)
≥3	56/397 (14.1)	171/1461 (11.7)
<b>Imaging variables</b>		
<b>ASPECTS subgroups, n (%)</b>		
0–4	23/408 (5.6)	93/1423 (6.5)
5–7	101/408 (24.7)	341/1423 (24)
8–10	284/408 (69.6)	989/1423 (69.5)
<b>Collateral score, n (%)</b>		
0% filling of the occluded territory	32/397 (8.1)	97/1381 (7)
>0% and ≤50% filling of the occluded territory	127/397 (32.0)	461/1381 (33.3)
>50% and <100% filling of the occluded territory	158/397 (39.8)	535/1381 (38.7)
100% filling of the occluded territory	80/397 (20.2)	282/1381 (20.9)
<b>Thrombus location, n (%)</b>		
ICA	101/407 (24.8)	395/1422 (27.8)
Proximal M1	97/407 (23.8)	364/1422 (25.6)

(Continued)

**Table 1. Continued**

	MR CLEAN Registry Subgroup Included (n=408)	Full MR CLEAN Registry Database (n=1488)
Distal M1	148/407 (36.4)	462/1422 (32.4)
M2	51/407 (12.5)	175/1422 (12.3)
M3	4/407 (1.0)	9/1422 (0.6)
A1/A2	6/407 (1.4)	6/1422 (0.4)
<b>Clot burden score, n (%)</b>		
0–4	97/353 (27.5)	371/1238 (30)
5–7	154/353 (43.6)	510/1238 (41.2)
8–10	102/353 (28.9)	357/1238 (28.8)
DT, median (IQR)	8.3 (0 to 14.4)	NA
Thrombus length, mm, median (IQR)	12.75 (8.7 to 17.9); n=408	NA
Thrombus absolute attenuation (HU), median (IQR)	51.8 (45 to 58); n=408	NA
Thrombus relative attenuation, median (IQR)	1.33 (1.19 to 1.52); n=408	NA
Thrombus perviousness (HU), median (IQR)	5.02 (–0.2 to 12.3); n=408	NA
<b>Treatment variables</b>		
Intravenous thrombolysis, n (%)	314/408 (77)	1161/1488 (78.0)
Time to artery puncture (minutes), median (IQR)	195 (150 to 251); n=408	208 (160 to 265); n=1488
<b>Performed procedure, n (%)</b>		
EVT with thrombus retrieval	356/408 (87.3)	1280/1488 (86)
Target occlusion not accessible	21/408 (5.1)	80/1488 (5.4)
No target occlusion depicted on DSA	27/408 (6.6)	119/1488 (8)
Other (procedure ended before attempt)	4/408 (1)	80/1488 (5.4)
Primary treatment modality, n (%)	334/356 (93.8)	1220/1280 (95.3)
Stent retriever	252/334 (75.4)	969/1220 (79.4)
Aspiration device	65/334 (19.4)	207/1220 (17)
Local delivery of the thrombolytic agent	4/334 (1.2)	10/1220 (0.8)
Different approach	13/334 (3.8)	34/1220 (2.8)
Duration of EVT (minutes), median (IQR)	62 (44 to 90); n=319	64 (40 to 90); n=1331

A1/A2 indicates occlusions in segment A1 or A2 of the anterior cerebral artery; ASPECTS, Alberta Stroke Program Early CT Score; DBP, diastolic blood pressure; DSA, digital subtraction angiography; DT, distance from the internal carotid artery terminus to the thrombus; EVT, endovascular treatment; HU, Hounsfield units; ICA, internal carotid artery; IQR, interquartile range; M1, segment M1 of the middle cerebral artery; M2, segment M2 of the middle cerebral artery; M3, segment M3 of the middle cerebral artery; MR CLEAN, Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; NA, not available; NIHSS, National Institutes of Health Stroke Scale; and SBP, systolic blood pressure.

Table 2. Associations of Thrombus Imaging Characteristics With Functional Outcome (Modified Rankin Scale) and Mortality at 90 Days

	Functional Outcome (mRS)								Mortality at 90 Days			
	Ordinal Regression (Shift to Better Outcome)				Binary Regression (Good Outcome, mRS Score of 0–2)				Binary Regression (Death)			
	Unadjusted Model		Adjusted Model*		Unadjusted Model		Adjusted Model*		Unadjusted Model		Adjusted Model*	
	cOR	95% CI	acOR	95% CI	OR	95% CI	aOR	95% CI	OR	95% CI	aOR	95% CI
Site of occlusion												
ICA	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
Proximal M1	1.97†	1.20–3.24†	2.44†	1.44–4.13†	1.88†	1.03–3.41†	2.35†	1.21–4.57†	0.44†	0.24–0.84†	0.29†	0.14–0.61†
Distal M1	2.44†	1.55–3.86†	3.27†	2.03–5.29†	2.26†	1.30–3.89†	3.17†	1.72–5.85†	0.35†	0.19–0.61†	0.19†	0.09–0.38†
M2	1.52	0.82–2.82	2.13†	1.11–4.09†	1.49	0.72–3.08	2.29†	1.02–5.14†	0.79	0.38–1.59	0.52	0.21–1.23
Other‡	2.01	0.52–7.81	3.91	0.96–15.84	2.05	0.43–9.78	2.98	0.47–18.85	0.63	0.08–3.11	0.21	0.01–2.30
CBS	1.12†	1.04–1.20†	1.15†	1.07–1.24†	1.12†	1.03–1.21†	1.16†	1.06–1.28†	0.91†	0.83–0.99†	0.85†	0.77–0.95†
DT	1.00	0.98–1.02	1.01	0.99–1.03	1.00	0.98–1.02	1.01	0.99–1.04	1.00	0.98–1.02	0.98	0.95–1.01
Length	0.98	0.96–1.00	0.96†	0.94–0.99†	0.98	0.96–1.01	0.96†	0.93–0.99†	1.01	0.98–1.04	1.04†	1.01–1.07†
Perviousness	1.01	0.99–1.02	1.01†	1.00–1.02†	1.01	0.99–1.02	1.01	0.99–1.02	1.00	0.99–1.01	0.99	0.98–1.01
Absolute attenuation	1.02	0.99–1.03	1.01	0.98–1.02	1.02	1.00–1.04	1.01	0.98–1.04	0.98	0.96–1.01	1.00	0.97–1.03
Relative attenuation	1.01	0.99–1.03	1.00	0.98–1.02	1.66	0.85–3.24	1.72	0.82–3.60	1.27	0.62–2.62	1.64	0.72–3.73

acOR indicates adjusted common odds ratio; aOR, adjusted odds ratio; CBS, clot burden score; cOR, common odds ratio; distal M1, distal M1 segment of middle cerebral artery; DT, distance from the internal carotid artery terminus to the thrombus; ICA, internal carotid artery; M2, M2 segment of middle cerebral artery; mRS, modified Rankin Scale at 90 d; proximal M1, proximal M1 segment of middle cerebral artery; and OR, odds ratio.

\*Adjusted for: age; prestroke mRS; intravenous thrombolysis; time from onset to groin puncture; previous history of stroke, atrial fibrillation, hypertension, diabetes mellitus, and myocardial infarction.

†P value <0.05.

‡M3 segment of middle cerebral artery or anterior cerebral artery.

Reperfusion Status

In patients who underwent thrombectomy, successful reperfusion was achieved in 60% (n=215/356). Only site of occlusion was significantly associated with successful reperfusion (Table 3). Proximal and distal M1 thrombi were associated with an increased likelihood of successful reperfusion compared with ICA thrombi (aOR, 2.60; 95% CI, 1.42–4.97 for proximal M1 thrombi and aOR, 1.96; 95% CI, 1.14–3.44 for distal M1 thrombi). No significant associations were observed between reperfusion and thrombus location in M2 or other segments. However, a trend towards an increased chance of successful reperfusion with a more distal thrombus location was observed.

Duration of Endovascular Procedure

Duration of EVT was significantly associated with thrombus location, CBS, and thrombus length (Table 3). Endovascular procedure was 14 to 15 minutes faster for distal M1 occlusions compared with ICA occlusions (adjusted coefficient B, -14.7; 95% CI, -24.2 to -5.1). For each 1 mm increase in thrombus length, there was an increase of ≈7 to 8 minutes in EVT duration (adjusted coefficient B, 7.3; 95% CI, 2.9–11.8). An increase of 1 point in CBS was associated with a reduction of ≈8 to 9 minutes of the duration of EVT (adjusted coefficient B, -8.5; 95% CI, -14.5 to -2.4).

Symptomatic Intracranial Hemorrhage

No significant associations were observed between thrombus imaging characteristics and sICH (Table 3).

Discussion

In the MR CLEAN Registry, thrombus imaging characteristics are associated with outcomes after EVT. A lower thrombus burden (ie, distal occlusion, shorter thrombus length, and higher CBS value) was associated with better functional outcome and faster endovascular procedure. A more pervious thrombus was also associated with favorable functional outcome. Only site of thrombus occlusion was significantly associated with reperfusion, in which a distal thrombus had a higher chance of successful reperfusion. We also demonstrated that a shorter thrombus is more likely to have a distal location, higher CBS, increased perviousness, and lower attenuation.

Associations of thrombus imaging characteristics with functional outcome and recanalization are well-described in patients treated with IVT, in whom failed recanalization and worse functional outcome were associated with low CBS, proximal thrombus location, longer thrombus length, and lower perviousness.<sup>3,6,8,9</sup> However, conflicting data about thrombus imaging characteristics and outcomes are observed in EVT. In accordance with our study, thrombi with a more distal location, shorter length, and higher CBS have been reported to be associated with improved functional outcome in patients who underwent EVT.<sup>6,18–20</sup> Conversely, some studies reported no association between functional outcome and thrombus length after EVT, however, they included only MCA thrombi.<sup>21,22</sup> In accordance with our study, longer endovascular procedural time has been associated with longer thrombus length.<sup>18</sup> The associations of thrombus characteristics with

**Table 3. Associations of Thrombus Imaging Characteristics With Successful Reperfusion, Duration of EVT, and sICH**

	Successful Reperfusion				Duration of EVT				sICH			
	Binary Regression				Linear Regression				Binary Regression			
	Unadjusted Model		Adjusted Model*		Unadjusted Model		Adjusted Model*		Unadjusted Model		Adjusted Model*	
	OR	95% CI	aOR	95% CI	B	95% CI	B	95% CI	OR	95% CI	aOR	95% CI
Site of occlusion												
ICA	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
Proximal M1	2.37†	1.35 to 4.25†	2.60†	1.42 to 4.97†	-14.58†	-19.9 to -4.3†	-14.62†	-25.1 to -4.1†	0.45	0.13 to 1.43	0.33	0.09 to 1.20
Distal M1	1.87†	1.12 to 3.13†	1.96†	1.14 to 3.44†	-15.17†	-24.6 to -6.3†	-14.68†	-24.2 to -5.1†	0.43	0.15 to 1.25	0.32	0.10 to 1.02
M2	1.34	0.68 to 2.65	1.55	0.74 to 3.32	-16.58†	-29.9 to -3.2†	-10.86	-24.3 to 2.6	0.42	0.08 to 2.00	0.38	0.07 to 1.98
Other‡	1.47	0.30 to 7.79	0.87	0.13 to 5.63	-31.58†	-60.6 to -2.6†	-21.32	-52.8 to 10.18	0.00	NA	0.00	NA
CBS	1.05	0.97 to 1.13	1.05	0.97 to 1.14	-9.18†	-15.0 to -3.3†	-8.47†	-14.5 to -2.4†	0.95	0.79 to 1.13	0.92	0.76 to 1.12
DT	0.98	0.96 to 1.01	0.98	0.95 to 1.01	-4.57	-10.3 to 1.2	-3.17	-9.0 to 2.7	0.98	0.91 to 1.06	0.99	0.90 to 1.08
Length	0.98	0.95 to 1.01	0.97	0.94 to 1.01	8.20†	3.7 to 12.7†	7.33†	2.9 to 11.8†	1.03	0.98 to 1.09	1.04	0.98 to 1.10
Perviousness	0.99	0.98 to 1.01	0.99	0.98 to 1.01	-1.22	-4.1 to 1.7	-0.61	-3.6 to 2.4	1.13	0.92 to 1.39	1.16	0.94 to 1.43
Absolute attenuation	1.01	0.98 to 1.03	1.00	0.98 to 1.02	4.62	-0.2 to 9.6	3.25	-1.8 to 8.3	1.01	0.99 to 1.03	1.01	0.99 to 1.03
Relative attenuation	1.31	0.67 to 2.57	1.35	0.65 to 2.79	0.27	-4.0 to 4.6	0.86	-3.6 to 5.3	0.91	0.21 to 4.04	0.84	0.16 to 4.25

aOR indicates adjusted odds ratio; B, regression coefficient B; CBS, clot burden score; distal M1, distal M1 segment of middle cerebral artery; DT, distance from the internal carotid artery terminus to the thrombus; EVT, endovascular treatment; ICA, internal carotid artery; M2, M2 segment of middle cerebral artery; proximal M1, proximal M1 segment of middle cerebral artery; OR, odds ratio; and sICH, symptomatic intracerebral hemorrhage.

\*Adjusted for: age; prestroke mRS; intravenous thrombolysis; time from onset to groin puncture; use of anticoagulants and antiplatelet agents; previous history of stroke, atrial fibrillation, hypertension, diabetes mellitus, and myocardial infarction.

†P value <0.05.

‡M3 segment of middle cerebral artery or anterior cerebral artery.

functional outcome and duration of EVT could be related to 2 possible mechanisms: (1) As demonstrated in our study, longer thrombi had a lower CBS and a more proximal location, and by virtue of their larger thrombus volume may simply be more difficult to retrieve, requiring more attempts and prolonging the procedural time, as shown previously<sup>18,23</sup> and (2) ICA and proximal M1 occlusions may result in decreased collateral flow via the anterior cerebral artery pial vessels<sup>14,15</sup> or lead to greater stroke volume because of the involvement of the lenticulostriate vessels, consequently leading to a higher NIHSS score and poor functional outcome.<sup>16,24</sup>

Conflicting data about the association of thrombus attenuation and perviousness with outcomes have been reported. Some studies have reported that successful reperfusion after EVT is more likely in hyperdense thrombi.<sup>25,26</sup> However, other reports, as well as the 2 largest published cohorts of thrombus attenuation assessments, are in line with our findings, showing that thrombus attenuation was not associated with reperfusion,<sup>6,21,27,28</sup> functional outcome, duration of EVT and sICH.<sup>21</sup> Different results about thrombus attenuation assessment might be because of variability in hematocrit levels, vessel calcification, and time of CT scan acquisition.<sup>29</sup> Further studies need to be performed before concluding that thrombus density is a not predictor of successful reperfusion and to evaluate the utility of this parameter in thrombectomy planning.

Thrombus perviousness has been associated with successful recanalization and improved functional outcome after IVT.<sup>3,5,19</sup> We observed an association between improved functional outcome and more pervious thrombi, yet no significant association was observed between thrombus perviousness and reperfusion after EVT. Likewise, despite a trend towards an increased chance of successful reperfusion with a more distal thrombus location, we observed no significant association between reperfusion and thrombus located in M2 or more distal segment. The absence of a significant effect of both thrombus perviousness and thrombus located in M2 or more distal segment on reperfusion may share an explanation since pervious thrombus, and more distal thrombus location was reported to be associated to one another,<sup>3</sup> as demonstrated in our study. Thrombi located in the M2 or M3 segments, and therefore, more pervious thrombi, are technically more difficult to reach during EVT because of their distal location and to the smaller diameter of these MCA segments.<sup>30,31</sup> Moreover, the use of IVT before EVT might increase the chance of thrombus fragility and thrombus migration especially in more pervious thrombi, leading to a higher frequency of clot inaccessibility by EVT, or thrombus fragmentation and thereby decreased eTICI scores.<sup>32</sup> Conversely, some studies have reported that IVT softens thrombi and thereby facilitates EVT.<sup>33</sup> Given that more pervious thrombi may be more sensitive to IVT, this effect may increase the

chance of reperfusion after EVT.<sup>19</sup> All these together might provide an explanation for the neutral effect of thrombus perviousness or distal location on reperfusion after EVT. However, further research is needed on this topic.

Our study has limitations. Many patients were excluded because of the absence of thin-section NCCT or CTA, prolonged time between the scanned NCCT and CTA (>30 minutes), poorly co-registered scans and poorly image quality. This might be explained by the fact the MRCLEAN Registry is a multicenter study, and not all centers saved or performed thin-slice NCCT/CTA, especially primary stroke centers. However, despite excluding a considerable number of patients, our study population is the largest sample to date about thrombus imaging characteristics in AIS treated by EVT, and it was a reliable sample of the entire MR CLEAN Registry, demonstrating similar baseline characteristics. An additional limitation is the use of CTA to assess CBS and thrombus length, which may be influenced by the backflow of a poor collateral circulation. However, overestimated CBS and length may strengthen the prognostic value of these thrombus characteristics because poor collaterals are known to be associated with poor outcomes.<sup>4,18</sup> For a more reliable measurement, dynamic CTA imaging might be a valuable alternative. Furthermore, accurate measurements of thrombus length are limited in curved or branched arteries. Although thrombus volume has been described to be a more accurate measure for thrombus burden, irrespective of angioarchitecture and collaterals, we think thrombus length and CBS are reasonable quantitative parameters for thrombus burden, and they might be more feasible in clinical practice in terms of rapidity and ease of use.<sup>18,22</sup> Differences in operator techniques, thrombectomy devices,<sup>10</sup> imaging parameters across institutions, may have led to distinct clot-retriever interactions and might have interfere with thrombus imaging assessments. However, this aspect of the study makes it more generalizable to real-world clinical practice. In our population, stent-retriever was by far the most performed modality, which may be a bias in the statistical analyses because of the unbalanced variation of EVT modalities. Our study does not account for operator differences. Further studies need to be done analyzing this operator and device variables. Finally, our data were gathered in routine clinical practice. Registries, in general, are prone to missing and incorrect values. However, all data were verified by our study coordinators and missing values were imputed.

### Conclusions

Imaging characteristics related to thrombus burden are associated with functional outcome and duration of endovascular procedure after thrombectomy for AIS. Distal site of occlusion, shorter thrombi, and higher CBS is associated with better functional outcome and faster endovascular procedure. Site of occlusion is strongly associated with reperfusion status, and pervious thrombus is associated with favorable functional outcome.

### Sources of Funding

The MR CLEAN registry (Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke) was partly funded by Stichting Toegepast Wetenschappelijk Instituut voor Neuromodulatie (TWIN) Foundation, Erasmus MC University

Medical Center, Maastricht University Medical Center, and Academic Medical Center, Amsterdam.

### Disclosures

Erasmus University Medical Center received funds from Stryker, Medtronic, Penumbra, Siemens for consultations by Drs van der Lugt and Dippel. Academic Medical Center Amsterdam received funds from Stryker for consultations by Drs Majoie and Roos. Maastricht University Medical Center received funds from Stryker and Codman for consultations by Dr van Zwam. Dr Majoie also reports research grants from the TWIN Foundation, the Netherlands Cardiovascular Research Committee (CVON)/Dutch Heart Foundation, the European Commission, and Stryker. Dr Dippel also reports research grants from Dutch Heart Foundation, Brain Foundation Netherlands, the Netherlands Organisation for Health Research and Development, and Health Holland Top Sector Life Sciences & Health, and unrestricted grants from AngioCare BV, Medtronic, Covidien/EV3, Medac GmbH/LAMEPRO, Penumbra Inc, Stryker, Top Medical/Concentric, Thrombolytic Science LLC, and Stryker European Operations BV. Dr Marquering is cofounder and shareholder of Nico-lab. Drs Jansen, Roos, and Majoie own stock in Nico-lab. Dr Yoo is a shareholder of Inera Therapeutics, received research grants from Medtronic, Cerenovus, Penumbra, Stryker, and Genentech, and received funds from Cerenovus and Genentech for consultations. The other authors report no conflicts.

### References

1. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al; American Heart Association Stroke Council. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2018;49:e46–e110. doi: 10.1161/STR.0000000000000158
2. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med*. 2015;372:11–20. doi: 10.1056/NEJMoa1411587
3. Santos EM, Marquering HA, den Blanken MD, Berkhemer OA, Boers AM, Yoo AJ, et al; MR CLEAN Investigators. Thrombus permeability is associated with improved functional outcome and recanalization in patients with ischemic stroke. *Stroke*. 2016;47:732–741. doi: 10.1161/STROKEAHA.115.011187
4. Treurniet KM, Yoo AJ, Berkhemer OA, Lingsma HF, Boers AM, Fransen PS, et al; MR CLEAN Investigators. Clot burden score on baseline computerized tomographic angiography and intra-arterial treatment effect in acute ischemic stroke. *Stroke*. 2016;47:2972–2978. doi: 10.1161/STROKEAHA.116.014565
5. Mishra SM, Dykeman J, Sajobi TT, Trivedi A, Almekhlafi M, Sohn SI, et al. Early reperfusion rates with IV tPA are determined by CTA clot characteristics. *AJNR Am J Neuroradiol*. 2014;35:2265–2272. doi: 10.3174/ajnr.A4048
6. Borst J, Berkhemer OA, Santos EMM, Yoo AJ, den Blanken M, Roos YBWEM, et al; MR CLEAN Investigators. Value of thrombus CT characteristics in patients with acute ischemic stroke. *AJNR Am J Neuroradiol*. 2017;38:1758–1764. doi: 10.3174/ajnr.A5331
7. Riedel CH, Zimmermann P, Jensen-Kondering U, Stinge R, Deuschl G, Jansen O. The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. *Stroke*. 2011;42:1775–1777. doi: 10.1161/STROKEAHA.110.609693
8. Rohan V, Baxa J, Tupy R, Cerna L, Sevcik P, Friesl M, et al. Length of occlusion predicts recanalization and outcome after intravenous thrombolysis in middle cerebral artery stroke. *Stroke*. 2014;45:2010–2017. doi: 10.1161/STROKEAHA.114.005731
9. Murphy A, Symons SP, Hopyan J, Aviv RI. Factors influencing clinically meaningful recanalization after IV-rtPA in acute ischemic stroke. *AJNR Am J Neuroradiol*. 2013;34:146–152. doi: 10.3174/ajnr.A3169
10. Jansen IGH, Mulder MJHL, Goldhoorn RB; MR CLEAN Registry Investigators. Endovascular treatment for acute ischaemic stroke in routine clinical practice: prospective, observational cohort study (MR CLEAN Registry). *BMJ*. 2018;360:k949. doi: 10.1136/bmj.k949
11. Klein S, Staring M, Murphy K, Viergever MA, Pluim JP. Elastix: a toolbox for intensity-based medical image registration. *IEEE Trans Med Imaging*. 2010;29:196–205. doi: 10.1109/TMI.2009.2035616



12. Noser EA, Shaltoni HM, Hall CE, Alexandrov A V., Garami Z, Cacayorin ED, et al. Aggressive mechanical clot disruption: a safe adjunct to thrombolytic therapy in acute stroke? *Stroke*. 2005;36:292–296.
13. Spiotta AM, Fiorella D, Arthur AS, Frei D, Turk AS, Hirsch JA. The semiotics of distal thrombectomy : towards a TICI score for the target vessel. *J Neurointerv Surg*. 2019;11:213–214.
14. Alves HC, Treurniet KM, Dutra BG, Jansen IGH, Boers AMM, Santos EMM, et al; MR CLEAN trial Investigators. Associations between collateral status and thrombus characteristics and their impact in anterior circulation stroke. *Stroke*. 2018;49:391–396. doi: 10.1161/STROKEAHA.117.019509
15. Qazi EM, Sohn SI, Mishra S, Almekhlafi MA, Eesa M, d'Esterre CD, et al. Thrombus characteristics are related to collaterals and angio-architecture in acute stroke. *Can J Neurol Sci*. 2015;42:381–388. doi: 10.1017/cjn.2015.291
16. Puetz V, Dzialowski I, Hill MD, Subramaniam S, Sylaja PN, Krol A, et al; Calgary CTA Study Group. Intracranial thrombus extent predicts clinical outcome, final infarct size and hemorrhagic transformation in ischemic stroke: the clot burden score. *Int J Stroke*. 2008;3:230–236. doi: 10.1111/j.1747-4949.2008.00221.x
17. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. *J Clin Epidemiol*. 2006;59:1087–1091. doi: 10.1016/j.jclinepi.2006.01.014
18. Yoo AJ, Khatri P, Mocco J, Zaidat OO, Gupta R, Frei D, et al; THERAPY Trial Investigators. Impact of thrombus length on outcomes after intra-arterial aspiration thrombectomy in the THERAPY trial. *Stroke*. 2017;48:1895–1900. doi: 10.1161/STROKEAHA.116.016253
19. Santos EM, Dankbaar JW, Treurniet KM, Horsch AD, Roos YB, Kappelle LJ, et al; DUST Investigators. Permeable thrombi are associated with higher intravenous recombinant tissue-type plasminogen activator treatment success in patients with acute ischemic stroke. *Stroke*. 2016;47:2058–2065. doi: 10.1161/STROKEAHA.116.013306
20. Menon BK, Al-Ajlan FS, Najm M, et al. Association of clinical, imaging, and thrombus characteristics with recanalization of visible intracranial occlusion in patients with acute ischemic stroke. *JAMA Neurol*. 2018;320:1017–1026.
21. Spiotta AM, Vargas J, Hawk H, Turner R, Chaudry MI, Battenhouse H, et al. Hounsfield unit value and clot length in the acutely occluded vessel and time required to achieve thrombectomy, complications and outcome. *J Neurointerv Surg*. 2014;6:423–427. doi: 10.1136/neurintsurg-2013-010765
22. Seker F, Pfaff J, Wolf M, Schönerberger S, Nagel S, Herweh C, et al. Impact of thrombus length on recanalization and clinical outcome following mechanical thrombectomy in acute ischemic stroke. *J Neurointerv Surg*. 2017;9:937–939. doi: 10.1136/neurintsurg-2016-012591
23. Baek JH, Yoo J, Song D, Kim YD, Nam HS, Kim BM, et al. Predictive value of thrombus volume for recanalization in stent retriever thrombectomy. *Sci Rep*. 2017;7:15938. doi: 10.1038/s41598-017-16274-9
24. Tan IY, Demchuk AM, Hopyan J, Zhang L, Gladstone D, Wong K, et al. CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. *AJNR Am J Neuroradiol*. 2009;30:525–531. doi: 10.3174/ajnr.A1408
25. Mokin M, Morr S, Natarajan SK, Lin N, Snyder KV, Hopkins LN, et al. Thrombus density predicts successful recanalization with solitaire stent retriever thrombectomy in acute ischemic stroke. *J Neurointerv Surg*. 2015;7:104–107. doi: 10.1136/neurintsurg-2013-011017
26. Froehler MT, Tateshima S, Duckwiler G, Jahan R, Gonzalez N, Vinuela F, et al; UCLA Stroke Investigators. The hyperdense vessel sign on CT predicts successful recanalization with the merci device in acute ischemic stroke. *J Neurointerv Surg*. 2013;5:289–293. doi: 10.1136/neurintsurg-2012-010313
27. Jagani M, Kallmes DF, Brinjikji W. Correlation between clot density and recanalization success or stroke etiology in acute ischemic stroke patients. *Interv Neuroradiol*. 2017;23:274–278. doi: 10.1177/1591019917694478
28. Yilmaz U, Roth C, Reith W, Papanagiotou P. Thrombus attenuation does not predict angiographic results of mechanical thrombectomy with stent retrievers. *AJNR Am J Neuroradiol*. 2013;34:2184–2186. doi: 10.3174/ajnr.A3565
29. Polito V, La Piana R, Del Pilar Cortes M, Tampieri D. Assessment of clot length with multiphase CT angiography in patients with acute ischemic stroke. *Neuroradiol J*. 2017;30:593–599. doi: 10.1177/1971400917736928
30. Coutinho JM, Liebeskind DS, Slater LA, Nogueira RG, Baxter BW, Levy EI, et al. Mechanical thrombectomy for isolated M2 occlusions: a post hoc analysis of the STAR, SWIFT, and SWIFT PRIME studies. *AJNR Am J Neuroradiol*. 2016;37:667–672. doi: 10.3174/ajnr.A4591
31. Compagne K, van der Sluijs P, van den Wijngaard I, Roozenbeek B, Mulder M, van Zwam WH, et al. The role of dominant caliber M2 segment occlusion in ischemic stroke. *Stroke*. 2019;50:419–427.
32. Kaesmacher J, Maegerlein C, Kaesmacher M, Zimmer C, Poppert H, Friedrich B, et al. Thrombus migration in the middle cerebral artery: incidence, imaging signs, and impact on success of endovascular thrombectomy. *J Am Heart Assoc*. 2017;6(2):e005149.
33. Pfefferkorn T, Holtmannspötter M, Patzig M, Brückmann H, Ottomeyer C, Opherk C, et al. Preceding intravenous thrombolysis facilitates endovascular mechanical recanalization in large intracranial artery occlusion. *Int J Stroke*. 2012;7:14–18. doi: 10.1111/j.1747-4949.2011.00639.x